Designed for specialist prescribers and clinicians, this advanced module evaluates the evidence base for medical cannabis across a spectrum of neurological disorders.
You will examine the role of the Endocannabinoid System (ECS) in modulating neural activity and critical data – ranging from rigorous RCTs for licensed indications (Dravet and Lennox-Gastaut syndromes, MS spasticity) to emerging Real-World Data (RWD) for off-label use in movement and sleep disorders.
By the end of this course you will be able to:
The Endocannabinoid System in Neurology
Licensed vs. Unlicensed Indications
The “Unmet Need” in Neurology
Drug-Resistant Epilepsy: The Challenge
Mechanisms: Modulating Excitability
Evidence Base: Epidyolex® & CBD
Safety: The CBD-Clobazam Interaction
Parkinson’s & Huntington’s Disease
Evidence Review: Motor vs. Non-Motor
Managing Symptom Clusters
Limitations of Current Research
The Role of the ECS in Sleep
Evidence Review: RCTs vs. Real-World Data
Dosing Strategies (Biphasic Effects)
Safety & Tolerance
Pathophysiology & Spasticity
Evidence Base: Sativex® & Cannabis
Managing Associated Symptoms (Pain/Bladder)
Safety & Nabiximols Specifics
Formulation Selection (Dexterity & Swallowing)
Titration: Epidyolex® & Sativex®
Unlicensed Dosing Protocols
Monitoring, Safety & Driving
Alongside this course, the Foundations of Medical Cannabis pathway includes additional courses that expand on history, biology, and clinical practice. Each is short, CPD Certified, and designed to build confidence step by step.